ArticleScientific reports2023

Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy.

Noam Tzuri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.